ClinicalTrials.gg

Program

lanoracopan

Its studies are mostly in Hemoglobinuria, Paroxysmal · Hepatic Insufficiency · Glomerulonephritis, IGA, led by Wuhan Createrna Science and Technology.

Furthest: phase 3, since Apr 9, 202511 company-led studies, 6 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wuhan Createrna Science and Technology116 open or runningphase 3since Apr 9, 2025Nov 30, 2022Dec 30, 2026phase 3 · NCT06933914

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 1 study in Hemoglobinuria, ParoxysmalFirst studyNCT05642585 · 63 enrolled · China
  2. Apr 13, 20232 phase 1 studies in Hemoglobinuria, ParoxysmalNCT05828485, NCT05828472
  3. Sep 11, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06050226 · 34 enrolled · China
  4. Nov 10, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06134414 · 40 planned
  5. Aug 2, 2024Phase 1 study in Hemoglobinuria, ParoxysmalNCT06543459 · 16 planned · China
  6. Nov 11, 2024Phase 2 study in Glomerulonephritis, IGANCT06687174 · 72 planned · China
  7. Apr 9, 20253 phase 3 studies in Hemoglobinuria, ParoxysmalNCT06932471, NCT06932744, NCT06933914
  8. May 9, 2026Phase 1 study in Hepatic InsufficiencyNCT07625618 · 24 enrolled · China

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT06933914
  2. Jul 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06134414

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07625618Hepatic Insufficiency · China1CompletedDec 28, 202424
NCT06933914Hemoglobinuria, Paroxysmal · China3RecruitingDec 30, 2026120
NCT06932744Hemoglobinuria, Paroxysmal · China3RecruitingDec 30, 202566
NCT06932471Hemoglobinuria, Paroxysmal · China3RecruitingDec 30, 202520
NCT06687174Glomerulonephritis, IGA · China2Not yet recruitingJun 15, 202672
NCT06543459Hemoglobinuria, Paroxysmal · China1Not yet recruitingSep 27, 202416
NCT06134414Hemoglobinuria, Paroxysmal2Not yet recruitingJul 202740
NCT06050226Hemoglobinuria, Paroxysmal · China2CompletedApr 30, 202434
NCT05828485Hemoglobinuria, Paroxysmal · China1CompletedOct 23, 202212
NCT05828472Hemoglobinuria, Paroxysmal · China1CompletedJun 30, 202340
NCT05642585Hemoglobinuria, Paroxysmal · China1CompletedJun 4, 202363

How it is read

Names in the registry

  • “MY008211A tablets”, 11 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.